Developing a new vaccine for Hepatitis C using nanoparticles and antibodies
Novel HCV vaccine antigens and nanoparticles
This study is working on a new vaccine for Hepatitis C that uses cutting-edge technology to help your immune system fight the virus better, and if it works, it could offer you protection against getting infected.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project ID | NIH-11015071 on NIH RePORTER |
What this research studies
This research focuses on creating a novel vaccine for Hepatitis C virus (HCV) by utilizing advanced techniques such as nanoparticle engineering and structural optimization of viral antigens. The approach involves designing vaccine components that can effectively stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HCV. By analyzing the structures of HCV proteins and their interactions with antibodies, the researchers aim to enhance the vaccine's ability to provoke a strong and lasting immune response. Patients may benefit from this innovative vaccine if it successfully provides protection against HCV infection.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk of Hepatitis C infection or those who have not yet been vaccinated against the virus.
Not a fit: Patients who are already infected with Hepatitis C or have received a previous vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to an effective vaccine that protects patients from Hepatitis C virus infection.
How similar studies have performed: Other research has shown promise in developing vaccines using similar approaches, but this specific method is innovative and aims to address gaps in current vaccine strategies.
Where this research is happening
La Jolla, United States
- Scripps Research Institute, the — La Jolla, United States (Active)
Researchers
- Principal investigator: Zhu, Jiang — Scripps Research Institute, the
- Study coordinator: Zhu, Jiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.